1
|
Murga-Zamalloa C, Webb S, Reneau J, Zevallos A, Danos-Diaz P, Perez-Silos V, Rodriguez M, Gao G, Fischer WN, Jandeleit B, Wilcox R. Successful anti-tumor effects with two novel bifunctional chemotherapeutic compounds that combine a LAT1 substrate with cytotoxic moieties in aggressive T-cell lymphomas. Leuk Res Rep 2023; 21:100398. [PMID: 38192502 PMCID: PMC10772281 DOI: 10.1016/j.lrr.2023.100398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2023] [Revised: 09/05/2023] [Accepted: 11/21/2023] [Indexed: 01/10/2024] Open
Abstract
T-cell lymphomas are aggressive neoplasms characterized by poor responses to current chemotherapeutic agents. Expression of the l-type amino acid transporter 1 (LAT 1, SLC7A5) allows for the expansion of healthy T-cell counterparts, and upregulation of LAT1 has been reported in precursor T-cell acute leukemia. Therefore, the expression of LAT1 was evaluated in a cohort of cutaneous and peripheral T-cell lymphomas. The findings demonstrated that LAT1 is upregulated in aggressive variants and absent in low-grade or indolent disease such as mycosis fungoides. In addition, upregulated LAT1 expression was seen in a large proportion of aggressive peripheral T-cell lymphomas, including peripheral T-cell lymphoma not otherwise specific (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL). The anti-tumor effects of two novel non-cleavable and bifunctional compounds, QBS10072S and QBS10096S, that combine a potent cytotoxic chemotherapeutic domain (tertiary N-bis(2-chloroethyl)amine) with the structural features of a selective LAT1 substrate (aromatic β-amino acid) were tested in vitro and in vivo in T-cell lymphoma cell lines. The findings demonstrated decreased survival of T-cell lymphoma lines with both compounds. Overall, the results demonstrate that LAT1 is a valuable biomarker for aggressive T-cell lymphoma counterparts and QBS10072S and QBS10096S are successful therapeutic options for these aggressive diseases.
Collapse
Affiliation(s)
- Carlos Murga-Zamalloa
- Department of Pathology, University of Illinois at Chicago, 840 S Wood Street, 260 CMET, Chicago, IL 60607, United States
| | - Shaun Webb
- Department of Pathology, University of Illinois at Chicago, 840 S Wood Street, 260 CMET, Chicago, IL 60607, United States
| | - John Reneau
- Department of Internal Medicine, Ohio State University, Columbus, OH 43210, United States
| | - Alejandro Zevallos
- Department of Pathology, University of Illinois at Chicago, 840 S Wood Street, 260 CMET, Chicago, IL 60607, United States
| | - Pierina Danos-Diaz
- Department of Pathology, University of Illinois at Chicago, 840 S Wood Street, 260 CMET, Chicago, IL 60607, United States
| | - Vanessa Perez-Silos
- Department of Pathology, University of Illinois at Chicago, 840 S Wood Street, 260 CMET, Chicago, IL 60607, United States
| | - Mirna Rodriguez
- Quadriga BioSciences, Inc., Los Altos CA 94022, United States
| | - Guangyao Gao
- Acme Bioscience, Inc., Palo Alto, CA 94303, United States
| | | | - Bernd Jandeleit
- Quadriga BioSciences, Inc., Los Altos CA 94022, United States
| | - Ryan Wilcox
- Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48105, United States
| |
Collapse
|
2
|
Deng J, Chernikova SB, Wang Y, Rodriguez ML, Andersen SJ, Umeh-Garcia MC, Godfrey BO, Ahmadian SS, Fischer WN, Koller KJ, Jandeleit B, Ringold GM, Gephart MH. A Novel Brain-Permeant Chemotherapeutic Agent for the Treatment of Brain Metastasis in Triple-Negative Breast Cancer. Mol Cancer Ther 2021; 20:2110-2116. [PMID: 34635566 DOI: 10.1158/1535-7163.mct-21-0140] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2021] [Revised: 06/18/2021] [Accepted: 07/26/2021] [Indexed: 02/05/2023]
Abstract
Development of metastases to central nervous system (CNS) is an increasing clinical issue following the diagnosis of advanced breast cancer. The propensity to metastasize to CNS varies by breast cancer subtype. Of the four breast cancer subtypes, triple-negative breast cancers (TNBC) have the highest rates of both parenchymal brain metastasis and leptomeningeal metastasis (LM). LM is rapidly fatal due to poor detection and limited therapeutic options. Therapy of TNBC brain metastasis and LM is challenged by multifocal brain metastasis and diffuse spread of LM, and must balance brain penetration, tumor cytotoxicity, and the avoidance of neurotoxicity. Thus, there is an urgent need for novel therapeutic options in TNBCs CNS metastasis. QBS10072S is a novel chemotherapeutic that leverages TNBC-specific defects in DNA repair and LAT1 (L-amino acid transporter type 1)-dependent transport into the brain. In our study, activity of QBS10072S was investigated in vitro with various cell lines including the human TNBC cell line MDA-MB-231 and its brain-tropic derivative MDA-MB-231-BR3. QBS10072S was preferentially toxic to TNBC cells. The efficacy of QBS10072S against brain metastasis and LM was tested using a model of brain metastasis based on the internal carotid injection of luciferase-expressing tumor cells into NuNu mice. The compound was well tolerated, delayed tumor growth and reduced leptomeningeal dissemination, resulting in significant extension of survival. Given that current treatments for LM are palliative with only few studies reporting a survival benefit, QBS10072S is planned to be investigated in clinical trials as a therapeutic for TNBC LM. SIGNIFICANCE: TNBC brain metastasis often involves dissemination into leptomeninges. Treatment options for TNBC leptomeningeal metastasis are limited and are mostly palliative. Our study demonstrates significant efficacy of the brain-penetrating agent QBS10072S against TNBC brain metastasis and leptomeningeal spread.
Collapse
Affiliation(s)
- Jiaojiao Deng
- Department of Neurosurgery, Stanford University, Stanford, California.,Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China
| | | | - Yuelong Wang
- Department of Neurosurgery, Stanford University, Stanford, California.,Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, China
| | | | | | | | - Bryanna O Godfrey
- Department of Neurosurgery, Stanford University, Stanford, California
| | - Saman S Ahmadian
- Department of Pathology, Stanford University, Stanford, California
| | | | | | | | | | | |
Collapse
|
3
|
Ozawa T, Rodriguez M, Zhao G, Yao TW, Fischer WN, Jandeleit B, Koller K, Nicolaides T. A Novel Blood-Brain Barrier-Permeable Chemotherapeutic Agent for the Treatment of Glioblastoma. Cureus 2021; 13:e17595. [PMID: 34646647 PMCID: PMC8482806 DOI: 10.7759/cureus.17595] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/30/2021] [Indexed: 02/04/2023] Open
Abstract
Introduction The standard treatment for glioblastoma (GBM) patients is surgical tumor resection, followed by radiation and chemotherapy with temozolomide (TMZ). Unfortunately, 60% of newly diagnosed GBM patients express high levels of the DNA repair enzyme O6-methylguanine-DNA methyltransferase (MGMT) and are TMZ-resistant, and all patients eventually become refractory to treatment. The blood-brain barrier (BBB) is an obstacle to the delivery of chemotherapeutic agents to GBM, and BBB-permeable agents that are efficacious in TMZ-resistant and refractory patients are needed. The large amino acid transporter 1 (LAT1) is expressed on the BBB and in GBM and is detected at much lower levels in normal brain tissue. A LAT1-selective therapeutic would potentially target brain tumors while avoiding uptake by healthy tissue. Methods We report a novel chemical entity (QBS10072S) that combines a potent cytotoxic chemotherapeutic domain (tertiary N-bis(2-chloroethyl)amine) with the structural features of a selective LAT1 substrate and tested it against GBM models in vitro and in vivo. For in vitro studies, DNA damage was assessed with a gamma H2A.X antibody and cell viability was assessed by WST-1 assay and/or CellTiter-Glo assay. For in vivo studies, QBS10072S (with or without radiation) was tested in orthotopic glioblastoma xenograft models, using overall survival and tumor size (as measured by bioluminescence), as endpoints. Results QBS10072S is 50-fold more selective for LAT1 vs. LAT2 in transport assays and demonstrates significant growth suppression in vitro of LAT1-expressing GBM cell lines. Unlike TMZ, QBS10072S is cytotoxic to cells with both high and low levels of MGMT expression. In orthotopic GBM xenografts, QBS10072S treatment significantly delayed tumorigenesis and prolonged animal survival compared to the vehicle without adverse effects. Conclusion QBS10072S is a novel BBB-permeable chemotherapeutic agent with the potential to treat TMZ-resistant and recurrent GBM as monotherapy or in combination with radiation treatment.
Collapse
Affiliation(s)
- Tomoko Ozawa
- Neurological Surgery, University of California San Francisco, San Francisco, USA
| | | | - Guisheng Zhao
- Pediatric Hematology-Oncology, New York University (NYU), New York, USA
| | | | | | | | | | | |
Collapse
|
4
|
Botas A, Eitel M, Schwarz PN, Buchmann A, Costales P, Núñez LE, Cortés J, Morís F, Krawiec M, Wolański M, Gust B, Rodriguez M, Fischer W, Jandeleit B, Zakrzewska‐Czerwińska J, Wohlleben W, Stegmann E, Koch P, Méndez C, Gross H. Genetic Engineering in Combination with Semi‐Synthesis Leads to a New Route for Gram‐Scale Production of the Immunosuppressive Natural Product Brasilicardin A. Angew Chem Int Ed Engl 2021. [DOI: 10.1002/ange.202015852] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Alma Botas
- Departamento de Biología Funcional e Instituto Universitario de Oncología del Principado de Asturias Universidad de Oviedo and Instituto de Investigación Sanitaria de Asturias (ISPA) c/ Julián Clavería s/n. 33006 Oviedo Spain
| | - Michael Eitel
- Department of Pharmaceutical Chemistry Institute of Pharmaceutical Sciences University of Tübingen Auf der Morgenstelle 8 72076 Tübingen Germany
| | - Paul N. Schwarz
- Department of Microbiology and Biotechnology Interfaculty Institute of Microbiology and Infection Medicine University of Tübingen Auf der Morgenstelle 28 72076 Tübingen Germany
| | - Anina Buchmann
- Department of Pharmaceutical Biology Institute of Pharmaceutical Sciences University of Tübingen Auf der Morgenstelle 8 72076 Tübingen Germany
| | - Paula Costales
- EntreChem S.L. Vivero Ciencias de la Salud c/ Colegio Santo Domingo de Guzmán, s/n 33011 Oviedo Spain
| | - Luz Elena Núñez
- EntreChem S.L. Vivero Ciencias de la Salud c/ Colegio Santo Domingo de Guzmán, s/n 33011 Oviedo Spain
| | - Jesús Cortés
- EntreChem S.L. Vivero Ciencias de la Salud c/ Colegio Santo Domingo de Guzmán, s/n 33011 Oviedo Spain
| | - Francisco Morís
- EntreChem S.L. Vivero Ciencias de la Salud c/ Colegio Santo Domingo de Guzmán, s/n 33011 Oviedo Spain
| | - Michał Krawiec
- Department of Molecular Microbiology Faculty of Biotechnology University of Wrocław ul. F. Joliot-Curie 14A 50-383 Wrocław Poland
| | - Marcin Wolański
- Department of Molecular Microbiology Faculty of Biotechnology University of Wrocław ul. F. Joliot-Curie 14A 50-383 Wrocław Poland
| | - Bertolt Gust
- Department of Pharmaceutical Biology Institute of Pharmaceutical Sciences University of Tübingen Auf der Morgenstelle 8 72076 Tübingen Germany
| | - Mirna Rodriguez
- Quadriga BioSciences, Inc. 339 S. San Antonio Road, Suite 2A Los Altos CA 94022 USA
| | - Wolf‐Nicolas Fischer
- Quadriga BioSciences, Inc. 339 S. San Antonio Road, Suite 2A Los Altos CA 94022 USA
| | - Bernd Jandeleit
- Quadriga BioSciences, Inc. 339 S. San Antonio Road, Suite 2A Los Altos CA 94022 USA
| | - Jolanta Zakrzewska‐Czerwińska
- Department of Molecular Microbiology Faculty of Biotechnology University of Wrocław ul. F. Joliot-Curie 14A 50-383 Wrocław Poland
| | - Wolfgang Wohlleben
- Department of Microbiology and Biotechnology Interfaculty Institute of Microbiology and Infection Medicine University of Tübingen Auf der Morgenstelle 28 72076 Tübingen Germany
| | - Evi Stegmann
- Department of Microbiology and Biotechnology Interfaculty Institute of Microbiology and Infection Medicine University of Tübingen Auf der Morgenstelle 28 72076 Tübingen Germany
| | - Pierre Koch
- Department of Pharmaceutical Chemistry Institute of Pharmaceutical Sciences University of Tübingen Auf der Morgenstelle 8 72076 Tübingen Germany
| | - Carmen Méndez
- Departamento de Biología Funcional e Instituto Universitario de Oncología del Principado de Asturias Universidad de Oviedo and Instituto de Investigación Sanitaria de Asturias (ISPA) c/ Julián Clavería s/n. 33006 Oviedo Spain
| | - Harald Gross
- Department of Pharmaceutical Biology Institute of Pharmaceutical Sciences University of Tübingen Auf der Morgenstelle 8 72076 Tübingen Germany
| |
Collapse
|
5
|
Botas A, Eitel M, Schwarz PN, Buchmann A, Costales P, Núñez LE, Cortés J, Morís F, Krawiec M, Wolański M, Gust B, Rodriguez M, Fischer W, Jandeleit B, Zakrzewska‐Czerwińska J, Wohlleben W, Stegmann E, Koch P, Méndez C, Gross H. Genetic Engineering in Combination with Semi-Synthesis Leads to a New Route for Gram-Scale Production of the Immunosuppressive Natural Product Brasilicardin A. Angew Chem Int Ed Engl 2021; 60:13536-13541. [PMID: 33768597 PMCID: PMC8251711 DOI: 10.1002/anie.202015852] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2020] [Revised: 02/28/2021] [Indexed: 01/01/2023]
Abstract
Brasilicardin A (1) consists of an unusual anti/syn/anti-perhydrophenanthrene skeleton with a carbohydrate side chain and an amino acid moiety. It exhibits potent immunosuppressive activity, yet its mode of action differs from standard drugs that are currently in use. Further pre-clinical evaluation of this promising, biologically active natural product is hampered by restricted access to the ready material, as its synthesis requires both a low-yielding fermentation process using a pathogenic organism and an elaborate, multi-step total synthesis. Our semi-synthetic approach included a) the heterologous expression of the brasilicardin A gene cluster in different non-pathogenic bacterial strains producing brasilicardin A aglycone (5) in excellent yield and b) the chemical transformation of the aglycone 5 into the trifluoroacetic acid salt of brasilicardin A (1 a) via a short and straightforward five-steps synthetic route. Additionally, we report the first preclinical data for brasilicardin A.
Collapse
Affiliation(s)
- Alma Botas
- Departamento de Biología Funcional e Instituto Universitario de Oncología del Principado de AsturiasUniversidad de Oviedo and Instituto de Investigación Sanitaria de Asturias (ISPA)c/ Julián Clavería s/n.33006OviedoSpain
| | - Michael Eitel
- Department of Pharmaceutical ChemistryInstitute of Pharmaceutical SciencesUniversity of TübingenAuf der Morgenstelle 872076TübingenGermany
| | - Paul N. Schwarz
- Department of Microbiology and BiotechnologyInterfaculty Institute of Microbiology and Infection MedicineUniversity of TübingenAuf der Morgenstelle 2872076TübingenGermany
| | - Anina Buchmann
- Department of Pharmaceutical BiologyInstitute of Pharmaceutical SciencesUniversity of TübingenAuf der Morgenstelle 872076TübingenGermany
| | - Paula Costales
- EntreChem S.L.Vivero Ciencias de la Saludc/ Colegio Santo Domingo de Guzmán, s/n33011OviedoSpain
| | - Luz Elena Núñez
- EntreChem S.L.Vivero Ciencias de la Saludc/ Colegio Santo Domingo de Guzmán, s/n33011OviedoSpain
| | - Jesús Cortés
- EntreChem S.L.Vivero Ciencias de la Saludc/ Colegio Santo Domingo de Guzmán, s/n33011OviedoSpain
| | - Francisco Morís
- EntreChem S.L.Vivero Ciencias de la Saludc/ Colegio Santo Domingo de Guzmán, s/n33011OviedoSpain
| | - Michał Krawiec
- Department of Molecular MicrobiologyFaculty of BiotechnologyUniversity of Wrocławul. F. Joliot-Curie 14A50-383WrocławPoland
| | - Marcin Wolański
- Department of Molecular MicrobiologyFaculty of BiotechnologyUniversity of Wrocławul. F. Joliot-Curie 14A50-383WrocławPoland
| | - Bertolt Gust
- Department of Pharmaceutical BiologyInstitute of Pharmaceutical SciencesUniversity of TübingenAuf der Morgenstelle 872076TübingenGermany
| | - Mirna Rodriguez
- Quadriga BioSciences, Inc.339 S. San Antonio Road, Suite 2ALos AltosCA94022USA
| | | | - Bernd Jandeleit
- Quadriga BioSciences, Inc.339 S. San Antonio Road, Suite 2ALos AltosCA94022USA
| | - Jolanta Zakrzewska‐Czerwińska
- Department of Molecular MicrobiologyFaculty of BiotechnologyUniversity of Wrocławul. F. Joliot-Curie 14A50-383WrocławPoland
| | - Wolfgang Wohlleben
- Department of Microbiology and BiotechnologyInterfaculty Institute of Microbiology and Infection MedicineUniversity of TübingenAuf der Morgenstelle 2872076TübingenGermany
| | - Evi Stegmann
- Department of Microbiology and BiotechnologyInterfaculty Institute of Microbiology and Infection MedicineUniversity of TübingenAuf der Morgenstelle 2872076TübingenGermany
| | - Pierre Koch
- Department of Pharmaceutical ChemistryInstitute of Pharmaceutical SciencesUniversity of TübingenAuf der Morgenstelle 872076TübingenGermany
| | - Carmen Méndez
- Departamento de Biología Funcional e Instituto Universitario de Oncología del Principado de AsturiasUniversidad de Oviedo and Instituto de Investigación Sanitaria de Asturias (ISPA)c/ Julián Clavería s/n.33006OviedoSpain
| | - Harald Gross
- Department of Pharmaceutical BiologyInstitute of Pharmaceutical SciencesUniversity of TübingenAuf der Morgenstelle 872076TübingenGermany
| |
Collapse
|
6
|
Deng J, Chernikova S, Fischer WN, Koller K, Jandeleit B, Ringold G, Hayden Gephart M. DDIS-31. A NOVEL BRAIN-PERMEANT CHEMOTHERAPEUTIC AGENT FOR THE TREATMENT OF BREAST CANCER LEPTOMENINGEAL METASTASIS. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz175.282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Leptomeningeal metastasis (LM), a spread of cancer to the cerebrospinal fluid and meninges, is universally and rapidly fatal due to poor detection and no effective treatment. Breast cancers account for a majority of LMs from solid tumors, with triple-negative breast cancers (TNBCs) having the highest propensity to metastasize to LM. The treatment of LM is challenged by poor drug penetration into CNS and high neurotoxicity. Therefore, there is an urgent need for new modalities and targeted therapies able to overcome the limitations of current treatment options. Quadriga has discovered a novel, brain-permeant chemotherapeutic agent that is currently in development as a potential treatment for glioblastoma (GBM). Recently, we have demonstrated dose-dependent in vitro and in vivo anti-tumor activity with various breast cancer cell lines including the human TNBC cell line MDA-MB-231. To evaluate the in vivo antitumor activity of the compound on LM, we used the mouse model of LM based on the internal carotid injection of luciferase-expressing MDA-MB-231-BR3 cells. Once the bioluminescence signal intensity from the metastatic spread reached (0.2 - 0.5) x 106photons/sec, mice were dosed i.v. (8 mg/kg once a week for nine weeks) or i.p. (4 or 8 mg/kg twice a week for nine weeks). Tumor growth was monitored by bioluminescence. The compound was well tolerated and caused a significant delay in metastatic growth resulting in significant extension of survival. Tumors regressed completely in ~ 28 % of treated animals in the i.p. group. Given that current treatments for LM are palliative with only few studies reporting a survival benefit, Quadriga’s new agent could be effective as a therapeutic for both primary and metastatic brain tumors such as LM. REF: https://onlinelibrary.wiley.com/doi/full/10.1002/pro6.43
Collapse
|
7
|
Deng J, Chernikova S, Fischer WN, Koller K, Jandeleit B, Ringold G, Gephart M. LPTO-06. A NOVEL BRAIN-PERMEANT CHEMOTHERAPEUTIC AGENT FOR THE TREATMENT OF BREAST CANCER LEPTOMENINGEAL METASTASIS. Neurooncol Adv 2019. [PMCID: PMC7213142 DOI: 10.1093/noajnl/vdz014.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Leptomeningeal metastasis (LM), a spread of cancer to the cerebrospinal fluid and meninges, is universally and rapidly fatal due to poor detection and no effective treatment. Breast cancers account for a majority of LMs from solid tumors, with triple-negative breast cancers (TNBCs) having the highest propensity to metastasize to LM. The treatment of LM is challenged by poor drug penetration into CNS and high neurotoxicity. Therefore, there is an urgent need for new modalities and targeted therapies able to overcome the limitations of current treatment options. Quadriga has discovered a novel, brain-permeant chemotherapeutic agent that is currently in development as a potential treatment for glioblastoma (GBM). The compound is active in suppressing the growth of GBM tumor cell lines implanted into the brain. Radiolabel distribution studies have shown significant tumor accumulation in intracranial brain tumors while sparing the adjacent normal brain tissue. Recently, we have demonstrated dose-dependent in vitro and in vivo anti-tumor activity with various breast cancer cell lines including the human TNBC cell line MDA-MB-231. To evaluate the in vivo antitumor activity of the compound on LM, we used the mouse model of LM based on the internal carotid injection of luciferase-expressing MDA-MB-231-BR3 cells. Once the bioluminescence signal intensity from the metastatic spread reached (0.2 - 0.5) x 106 photons/sec, mice were dosed i.p. twice a week with either 4 or 8 mg/kg for nine weeks. Tumor growth was monitored by bioluminescence. The compound was well tolerated and caused a significant delay in metastatic growth resulting in significant extension of survival. Tumors regressed completely in ~ 28 % of treated animals. Given that current treatments for LM are palliative with only few studies reporting a survival benefit, Quadriga’s new agent could be effective as a therapeutic for both primary and metastatic brain tumors such as LM. REF: https://onlinelibrary.wiley.com/doi/full/10.1002/pro6.43
Collapse
|
8
|
Nicolaides TP, Ozawa T, Yao TW, Prados M, Fischer WN, Jandeleit B, Koller K. Abstract B125: A novel BBB-permeable chemotherapeutic agent for the treatment of CNS tumors. Mol Cancer Ther 2018. [DOI: 10.1158/1535-7163.targ-17-b125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Standard of care for glioblastoma multiforme (GBM) patients is surgical tumor resection, followed by radiation and chemotherapy with temozolomide. Unfortunately, 60% of newly diagnosed GBM patients express high levels of the DNA repair enzyme MGMT and are temozolomide-insensitive, and all patients eventually become refractory to treatment. The blood-brain barrier (BBB) remains an obstacle to adequate delivery of chemotherapeutic agents to brain tumors. Lipophilic drugs such as temozolomide and lomustine are able to cross the BBB based on passive diffusion; however, their tissue distribution also causes toxicity to critical systemic organs, such as the bone marrow, leading to dose-limiting toxicity. Therefore, BBB-permeable chemotherapeutic agents that are efficacious in temozolomide-insensitive and refractory patients are needed. The large amino acid transporter 1 (LAT1) is highly expressed on the BBB and in GBM and other malignant brain tumors such as diffuse intrinsic pontine glioma (DIPG), where it is associated with poor prognosis, but is undetectable in normal brain tissue. Targeting LAT1 transport, while avoiding interaction with other closely related transporters expressed on normal tissue such as LAT2, will target brain tumors and avoid uptake into healthy tissue. We report the generation of a novel molecule (QBS10072S) that combines a potent cytotoxic domain with the structural features of a selective LAT1 substrate. QBS10072S is 50-fold more selective for LAT1 vs. LAT2 in transport assays, and demonstrates significant in vitro cytotoxicity to LAT1-expressing GBM cell lines and minimal cytotoxicity to normal human astrocytes (LAT1-negative). Unlike temozolomide, QBS10072S is cytotoxic to cells with both high and low levels of MGMT expression. In orthotopic glioblastoma xenografts, QBS10072S causes significant delay in tumor growth and increase in mouse survival compared to vehicle. QBS10072S is well tolerated, with no toxicity seen in normal brain or the BBB. In summary, QBS10072S is a novel BBB-permeable chemotherapeutic agent with the potential to treat temozolomide-insensitive and recurrent GBM.
Citation Format: Theodore P. Nicolaides, Tomoko Ozawa, Tsun Wen Yao, Michael Prados, Wolf-Nicolas Fischer, Bernd Jandeleit, Kerry Koller. A novel BBB-permeable chemotherapeutic agent for the treatment of CNS tumors [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2017 Oct 26-30; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr B125.
Collapse
|
9
|
Nicolaides T, Ozawa T, Prados M, Yao TW, Fischer WN, Jandeleit B, Koller K. DDIS-03. A NOVEL BBB-PERMEABLE CHEMOTHERAPEUTIC AGENT FOR THE TREATMENT OF GLIOBLASTOMA. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now212.194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
10
|
Bhat L, Jandeleit B, Dias TM, Moors TL, Gallop MA. Synthesis and biological evaluation of novel steroidal pyrazoles as substrates for bile acid transporters. Bioorg Med Chem Lett 2005; 15:85-7. [PMID: 15582416 DOI: 10.1016/j.bmcl.2004.10.027] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2004] [Revised: 10/05/2004] [Accepted: 10/09/2004] [Indexed: 01/20/2023]
Abstract
A series of novel steroidal pyrazoles was synthesized as substrates for bile acid transporters to explore their potential as drug carriers. The selected pyrazole fused bile acids were further conjugated with drugs and drug surrogates. Their in vitro transport activities were evaluated in human ileal bile acid transporter (hIBAT) and human liver bile acid transporter (hLBAT) expressing Chinese hamster ovary (CHO)-cells and Xenopus laevis oocytes. The results of synthetic efforts and transporter assays studies are described herein.
Collapse
|
11
|
Enders D, Jandeleit B, von Berg S, Raabe G, Runsink J. Iron-Mediated Allylic Substitution Reactions with Chirality Transfer. Stereochemistry of the Formation of Diastereo- and Enantiomerically Enriched Olefinic and Allylic Tetracarbonyl Iron Complexes. Organometallics 2001. [DOI: 10.1021/om010343l] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Dieter Enders
- Institut für Organische Chemie der Rheinisch-Westfälischen Technischen Hochschule, Professor-Pirlet Strasse 1, D-52074 Aachen, Germany
| | - Bernd Jandeleit
- Institut für Organische Chemie der Rheinisch-Westfälischen Technischen Hochschule, Professor-Pirlet Strasse 1, D-52074 Aachen, Germany
| | - Stefan von Berg
- Institut für Organische Chemie der Rheinisch-Westfälischen Technischen Hochschule, Professor-Pirlet Strasse 1, D-52074 Aachen, Germany
| | - Gerhard Raabe
- Institut für Organische Chemie der Rheinisch-Westfälischen Technischen Hochschule, Professor-Pirlet Strasse 1, D-52074 Aachen, Germany
| | - Jan Runsink
- Institut für Organische Chemie der Rheinisch-Westfälischen Technischen Hochschule, Professor-Pirlet Strasse 1, D-52074 Aachen, Germany
| |
Collapse
|
12
|
|
13
|
|
14
|
Affiliation(s)
- Bernd Jandeleit
- Symyx Technologies, 3100 Central Expressway, Santa Clara, CA 95051 (USA), Fax: (+1) 408‐748‐0175
| | - Dieter J. Schaefer
- Symyx Technologies, 3100 Central Expressway, Santa Clara, CA 95051 (USA), Fax: (+1) 408‐748‐0175
| | - Timothy S. Powers
- Symyx Technologies, 3100 Central Expressway, Santa Clara, CA 95051 (USA), Fax: (+1) 408‐748‐0175
| | - Howard W. Turner
- Symyx Technologies, 3100 Central Expressway, Santa Clara, CA 95051 (USA), Fax: (+1) 408‐748‐0175
| | - W. Henry Weinberg
- Symyx Technologies, 3100 Central Expressway, Santa Clara, CA 95051 (USA), Fax: (+1) 408‐748‐0175
| |
Collapse
|
15
|
Nicolaou KC, Trujillo JI, Jandeleit B, Chibale K, Rosenfeld M, Diefenbach B, Cheresh DA, Goodman SL. Design, synthesis and biological evaluation of nonpeptide integrin antagonists. Bioorg Med Chem 1998; 6:1185-208. [PMID: 9784861 DOI: 10.1016/s0968-0896(98)00090-x] [Citation(s) in RCA: 57] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
Recent studies demonstrated that peptide and antibody antagonists of integrin alpha v beta 3 block angiogenesis and tumor growth. In this article, the design, synthesis and biological evaluation of a series of nitroaryl ether-based, nonpeptide mimetics are described. The design of these compounds was based on Merck's arylether/alpha-aminoacid/guanidine framework and incorporates a novel nitroaryl system. The synthesized mimetics were tested against a variety of integrins (alpha v beta 3, alpha IIb beta 3, and alpha v beta 5) in order to determine their binding selectivity and ability to inhibit cell adhesion. Selected compounds were also tested for their ability to inhibit angiogenesis in vivo in the CAM (chick chorioallantoic membrane) assay. From the generated compound library, compounds 16 and 19 proved to be potent and selective inhibitors of alpha IIb beta 3 (IC50 = 14 nM) whereas compound 11 showed excellent in vivo inhibition of angiogenesis (at 30 micrograms/embryo).
Collapse
Affiliation(s)
- K C Nicolaou
- Department of Chemistry, Scripps Research Institute, La Jolla, CA 92037, USA
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Enders D, Baus U, Müller P, Nicolaou K, Jandeleit B. Asymmetric Synthesis of 3-Substituted 4-Oxoesters Using the SAMP-/RAMP-Hydrazone Method. ACTA ACUST UNITED AC 1998. [DOI: 10.1007/s007830050049] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
17
|
Nicolaou KC, Härter MW, Boulton L, Jandeleit B. Synthesis of the Bicyclic Core of CP-225,917 and CP-263,114 by an Intramolecular Diels–Alder Reaction. ACTA ACUST UNITED AC 1997. [DOI: 10.1002/anie.199711941] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
18
|
Nicolaou KC, Härter MW, Boulton L, Jandeleit B. Synthese des bicyclischen Gerüstes von CP-225,917 und CP-263,114 durch intramolekulare Diels-Alder-Reaktion. Angew Chem Int Ed Engl 1997. [DOI: 10.1002/ange.19971091117] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
19
|
Enders D, Frank U, Fey P, Jandeleit B, Lohray BB. Synthesis of highly diastereo- and enantiomerically enriched tetracarbonyl(η3-allyl)iron(1+) complexes for allylic substitutions with silyl enol ethers and silyl ketene acetals. J Organomet Chem 1996. [DOI: 10.1016/s0022-328x(96)06161-x] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
20
|
Enders D, Fey P, Schmitz T, Lohray BB, Jandeleit B. Regio- and stereoselective a4-umpolung reactions of α,β-unsaturated esters to 1,6-dicarbonyl compounds by addition of enantiopure nucleophiles to racemic tetracarbonyl (η3-alyl)iron(1+) complexes. J Organomet Chem 1996. [DOI: 10.1016/0022-328x(95)06042-u] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
21
|
Enders D, Berg SV, Jandeleit B. Iron-Mediated Allylic Substitutions with Complete Chirality Transfer. Synthesis of Functionalized γ-Substituted Alkenylsulfones of High Enantiomeric Purity. Synlett 1996. [DOI: 10.1055/s-1996-5313] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
22
|
Enders D, Jandeleit B. Efficient and convergent synthesis of (R)-(−)-10-methyltridecan-2-one, the sex pheromone of the spotted cucumber beetle, by iron-mediated chirality transfer. ACTA ACUST UNITED AC 1995. [DOI: 10.1002/jlac.1995199507159] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
23
|
Enders D, Jandeleit B, Raabe G. Iron-Promoted, Regio- and Stereoselective Allylic Substitutions for the Synthesis of Alkenyl Sulfones Substituted at C-3. ACTA ACUST UNITED AC 1994. [DOI: 10.1002/anie.199419491] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
24
|
Enders D, Jandeleit B, Raabe G. Eisen-unterstützte, regio- und stereoselektive allylische Substitutionen zu 3-substituierten Alkenylsulfonen. Angew Chem Int Ed Engl 1994. [DOI: 10.1002/ange.19941061914] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
25
|
Enders D, Jandeleit B. Iron-Mediated Complete Chirality Transfer in Allylic Substitutions. Efficient Synthesis of (-)-(S)-Myoporone. SYNTHESIS-STUTTGART 1994. [DOI: 10.1055/s-1994-25689] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|